Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Clinical trial NCT02787551 · COMPLETED
Trial details
- NCT number
- NCT02787551
- Sponsor
- Sanofi
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-06
- Primary completion
- 2018-05-25
- Enrollment
- 514
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.